Unlock instant, AI-driven research and patent intelligence for your innovation.

Use of TGF-beta and growth factor in treatment and prevention of intestinal mucosa diseases

A growth factor, transforming growth factor technology, applied in the field of TGF-β and growth factor in the treatment and prevention of intestinal mucosal diseases, can solve the problems of unstable growth factor, unsatisfactory bioavailability and so on

Inactive Publication Date: 2007-02-14
NV NUTRICIA +1
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The disadvantage of the method of this document is the preferred use of growth factors obtained from recombinant techniques
However, this type of growth factor has been shown to be less stable during sterilization treatments
Moreover, the bioavailability of these growth factors in the gastrointestinal tract is not satisfactory

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0016] specific implementation plan

[0017] According to a preferred embodiment of the present invention, the first pharmaceutical composition comprises TGF-beta in the substantial absence of AGF. AGF refers to any anabolic growth factor, ie any growth factor that promotes cell growth. Examples are: IGF-1, insulin-like growth factor 2 (IGF-2), growth hormone, epithelial growth factor (EGF), transforming growth factor alpha (TGF-α), mammalian milk growth factor (MMGF=β- animal cellulose) and fibroblast growth factor (FGF). For example, EGF is described in EP 0546 068 and MMGF is described in WO99 / 24470. The ratio TGF-β / AGF is preferably at least 50.

[0018] Preferably, the AGF in the second pharmaceutical composition is IGF-1. This means that preferably at least IGF-1 is present in the second pharmaceutical composition.

[0019] According to the invention, when reference is made to growth factors, active peptide analogues of these growth factors are also included. Pepti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the use of transforming growth factor beta (TGF- beta ) and anabolic growth factors (AGF) in the treatment and / or prevention of malfunction or disease of the intestinal mucosa. More in particular the invention relates to the treatment and / or prevention of damage of the intestinal mucosa as a result of chemotherapy of radiotherapy or of inflammatory bowel diseases with a product comprising: a) a first pharmaceutical composition comprising TGF- beta in the substantial absence of insulin-like growth factor-1(IGF-1); b) a second pharmaceutical composition comprising AGF in the substantial absence of TGF- beta ; wherein the first and second compositions are administered sequentially.

Description

[0001] This application is a divisional application of the Chinese patent application 00814004.9 filed on October 6, 2000, and the invention title is "Use of TGF-β and Growth Factors in the Treatment and Prevention of Intestinal Mucosa Diseases". technical field [0002] The present invention relates to compositions containing transforming growth factor beta (TGF-β) and compositions containing anabolic growth factors (AGF), especially insulin-like growth factor 1 (IGF-1) in the prevention or treatment of intestinal mucosal dysfunction or Use in diseases of the intestinal mucosa. The invention also relates to compositions containing TGF-beta and specific fibers and / or immunoglobulins and / or calcium, which can also be used in this therapy, especially in combination with IGF-1. Compositions containing TGF-[beta] are administered over a period of time when it is desired to inhibit cell proliferation and stimulate cell differentiation. Compositions containing IGF-1 are administere...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/18A61K35/20A61P1/04A61K47/16A61K33/06A61K36/00A61K36/899A61K38/00A61K38/30A61K38/40A61K39/395A61K47/36
CPCA61K38/1841A61K38/40A61K38/30A61K36/899A61P1/00A61P1/04A61P1/12A61K2300/00
Inventor 马尔滕·安妮·霍耶尔罗伯特·约翰·约瑟夫·哈格曼鲁道夫·莱昂纳德斯·洛德韦克·斯梅茨
Owner NV NUTRICIA